BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27615005)

  • 1. Research on radiotherapy at different times of the day for inoperable cervical cancer.
    Chang L; Li L; Li W; Jiang M; Jv Y; Wang L; Hou Y; Long Q; Yu S
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):856-864. PubMed ID: 27615005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric and Ki-67 immunohistochemical analysis of cell cycle distribution of cervical cancer during radiation therapy.
    Higuchi KH; Nakano T; Tsuboi A; Suzuki Y; Ohno T; Oka K
    Anticancer Res; 2001; 21(4A):2511-8. PubMed ID: 11724315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous 7-days-a-week external beam irradiation in locally advanced cervical cancer: final results of the Phase I/II study.
    Serkies K; Dziadziuszko R; Jassem J
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1256-61. PubMed ID: 21570204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma.
    Shukla P; Gupta D; Bisht SS; Pant MC; Bhatt ML; Gupta R; Srivastava K; Gupta S; Dhawan A; Mishra D; Negi MP
    Cancer; 2010 Apr; 116(8):2031-5. PubMed ID: 20162717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
    Zhang M; Xu HD; Pan SD; Lin S; Yue JH; Liu JR
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):966-71. PubMed ID: 22138462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.
    Dobrowsky W; Huigol NG; Jayatilake RS; Kizilbash NI; Okkan S; Kagiya VT; Tatsuzaki H
    Radiother Oncol; 2007 Jan; 82(1):24-9. PubMed ID: 17161478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).
    Bjarnason GA; Mackenzie RG; Nabid A; Hodson ID; El-Sayed S; Grimard L; Brundage M; Wright J; Hay J; Ganguly P; Leong C; Wilson J; Jordan RC; Walker M; Tu D; Parulekar W;
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):166-72. PubMed ID: 18805649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-escalation of the cumulative central radiation dose according to the tumor response can reduce rectal toxicity without compromising the treatment outcome in patients with uterine cervical cancer.
    Kim KH; Kim S; Kim GE; Koom WS; Kim SW; Nam EJ; Suh CO; Kim YB
    Gynecol Oncol; 2015 Dec; 139(3):439-46. PubMed ID: 26456139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
    Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate brachytherapy in uterine cervical carcinoma.
    Patel FD; Rai B; Mallick I; Sharma SC
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):125-30. PubMed ID: 15850912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
    Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences.
    Sorbe B; Bohr L; Karlsson L; Bermark B
    Int J Oncol; 2010 Feb; 36(2):371-8. PubMed ID: 20043071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six fractions per week of external beam radiotherapy and high-dose-rate brachytherapy for carcinoma of the uterine cervix: A phase I/II study.
    Yoon SM; Huh SJ; Park W; Lee JE; Park YJ; Nam HR; Lim DH; Ahn YC
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1508-13. PubMed ID: 16793216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G2/M cell cycle checkpoint is functional in cervical cancer patients after initiation of external beam radiotherapy.
    Cerciello F; Hofstetter B; Fatah SA; Zaghloul M; Odermatt B; Bodis S; Varga Z; Pruschy M; Ciernik IF
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1390-8. PubMed ID: 16029798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II trial of concurrent chemoradiation in the treatment of locally advanced carcinoma of uterine cervix: an experience from India.
    Saibishkumar EP; Patel FD; Sharma SC
    Bull Cancer; 2005 Jan; 92(1):E7-12. PubMed ID: 15811845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.